Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and recent acquisitions designed to broaden its addressable market beyond ENHANZE. 2026 revenue and profitability framework CEO Helen Torley reiterated the company's outlook for the current year, calling Halozyme's trajectory “a growth story” expected to continue for “many years to come.” The company is forecasting $1.7 billion to $1.8 billion in total revenue , which it described as 22% to 30% year-over-year growth . Torley said the increase is primarily driven by royalties from partnered products enabled by Halozyme's ENHANZE technology, with royalties expected to be $1.1 billion to $1.2 billion , growing at a 30% to 35% rate ? Data Storage to Data Intelligence: Everpure's Big AI Era Rebrand She also emphasized profitability inherent in the royalty model, noting that Halozyme expects adjust
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial OfficerPR Newswire
- Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 3/12/26 - Form 8-K
- 3/10/26 - Form 4
- 3/10/26 - Form 144
- HALO's page on the SEC website